Pharmala Biotech Holdings Inc
CNSX:MDMA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Pharmala Biotech Holdings Inc
Research & Development
Pharmala Biotech Holdings Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
P
|
Pharmala Biotech Holdings Inc
CNSX:MDMA
|
Research & Development
-CA$243.9k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Research & Development
-$629m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-7%
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
Research & Development
-$300.9m
|
CAGR 3-Years
-42%
|
CAGR 5-Years
-43%
|
CAGR 10-Years
-35%
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Research & Development
-CA$29m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
-27%
|
|
|
Spectral Medical Inc
TSX:EDT
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Cipher Pharmaceuticals Inc
TSX:CPH
|
Research & Development
-$21k
|
CAGR 3-Years
33%
|
CAGR 5-Years
31%
|
CAGR 10-Years
35%
|
|
Pharmala Biotech Holdings Inc
Glance View
PharmAla Biotech Holdings Inc. is a Canada-based biotechnology company. The Company is focused on the research, development, and manufacturing of methylenedioxy phenethylamines (MDXX)-class molecules, including methylenedioxy methamphetamine (MDMA). The Company is involved in sourcing finished clinical-grade LaNeo MDMA Drug Products in North America. Its drug active pharmaceutical ingredients (API) are encapsulated under GMP conditions and are available to entities who have Controlled Substances licenses, Section 56 Ministerial Exemptions, or Clinical Trial numbers within Canada. It works with laboratories across Canada to develop processes for the supply of LaNeo MDMA and other MDXX substances.
See Also
What is Pharmala Biotech Holdings Inc's Research & Development?
Research & Development
-243.9k
CAD
Based on the financial report for Aug 31, 2025, Pharmala Biotech Holdings Inc's Research & Development amounts to -243.9k CAD.
What is Pharmala Biotech Holdings Inc's Research & Development growth rate?
Research & Development CAGR 1Y
-95%
Over the last year, the Research & Development growth was -95%.
